s-14

PDE7 inhibitor S14 is a cell-permeable PDE7 inhibitor that acts by targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element-binding protein (CREB) pathway.

TF-S14 是一种 RORγt 的反向激动剂，它通过结合 RORγt 并抑制其活性来减少 Th17 细胞相关细胞因子的产生，包括 IL-17A、IL-21 和 IL-22。TF-S14 可用于研究自身免疫疾病和同种异体移植中的排斥反应。

GNS-1481为一种新型EGFR激酶抑制剂，专门针对EGFR的T790M突变异构体。

WMS-1405是ifenprodil的衍生物。作为一种高效的NR2B选择性NMDA受体拮抗剂，WMS-1405展示出了5.4 nM的Ki值。通过中心构建基块合成，WMS-1405由于其基本氮原子与苯基残基之间的特定距离，显示出高NR2B亲和性。WMS-1405具有成为治疗兴奋毒性的NMDA拮抗剂的潜力。

MRS-1477 is used as a TRPV1 positive allosteric modulator (PAM).

S-14671 is a 5-HT1A receptor agonist (pKi = 9.3) with high efficacy and exceptional in vivo potency. S-14671 also acts as a 5-HT2A and 5-HT2C receptor antagonist (both are pKi = 7.8).

UNBS-1450 is a sodium channel antagonist. UNBS-1450 is a hemi-synthetic cardenolide derived from 2″-oxovorusharin, it is effective against various cancer cell types with an excellent differential toxicity. At low nanomolar concentrations, UNBS-1450 induce

IS-145 is a thromboxane A2 receptor antagonist.

GBS-149 is a novel non-toxic and mammalian-specific LINE-1 inhibitor.

Inobrodib (CBP-IN-1) 是一种口服活性的强选择性p300/CBP 抑制剂，与 p300 和 CBP 结合，Kd 值为 1.3 和 1.7 nM。它抑制前列腺癌细胞系的细胞增殖并降低雄激素受体和 C-MYC 调节的基因表达。

6-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-1H-pyridine-3,4-dicarbonitrile 是一种生物活性化合物，可用于化学和生命科学领域的研究。

Fenclozine Maleate (S 1429) 是一种潜在的组胺H1受体拮抗剂 ，可用于研究发热、炎症和疼痛。

Benazepril hydrochloride (CGS 14824A HCl) 是一种血管紧张素转化酶（ACE）抑制剂，能够作用于高血压。

S 14506 hydrochloride 是一种5-HT1A 受体完全激动剂。

(2S,3S)-Pterosin S 14-O-glucoside 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T124536。

cIAP1 Ligand-Linker Conjugates 14 consist of an IAP ligand that targets the E3 ubiquitin ligase and a PROTAC linker. These conjugates, known as cIAP1 Ligand-Linker Conjugates 14, are used in the development of SNIPERs[1].

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized compound, designed as an E3 ligase ligand-linker conjugate, integrating the cereblon ligand derived from Pomalidomide and a linker employed in PROTAC technology. This compound serves to facilitate targeted protein degradation through the modulation of E3 ligase activity, enabling the selective elimination of specific proteins of interest.

Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is an E3 ligase ligand-linker conjugate which is designed using Thalidomide-based cereblon ligand and a 3-unit PEG linker. This compound is synthesized specifically for utilization in PROTAC technology.

VH032-thiol-C6-NH2, also known as VHL Ligand-Linker Conjugates 14, is a synthesized compound that functions as an E3 ligase ligand-linker conjugate. This compound combines the VH032 based VHL ligand with a linker commonly utilized in PROTAC technology.

Benazeprilat(CGS 14831) 是一种具有口服活性的贝那普利活性代谢物。Benazeprilat 具有高效的抗血压活性，可与其他其他类别的化合物（包括噻嗪类利尿剂和钙通道阻滞剂）联合使用来减少与心血管风险和继发性终末器官损伤相关的疾病的发生。Benazeprilat 可能用于研究急性左心室衰竭。

RS14203为一种IV型环核苷酸磷酸二酯酶(PDE IV)抑制剂，具有口服活性，其主要作用是诱导呕吐。

AS1411-C4-VH032（AS1411-VH032）通过促进MDM2的肿瘤选择性降解，有效缩小肿瘤体积，且未观察到明显毒性。

Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) 是一种可穿越血脑屏障且具口服活性的EGFR抑制剂。它通过抑制 p-EGFR、p-AKT 和 p-ERK 信号通路而诱导细胞凋亡 (Apoptosis)。在小鼠 H1975-luc BM 异种移植模型中，Lazertinib (mesylate) 显示出抗肿瘤活性。该化合物可用于非小细胞肺癌的研究。

Benazepril inhibits the activity of circulating angiotensin-converting enzyme (ACE) in horses.